Occupational Activity
AstraZeneca Cancels £450 Million UK Vaccine Plant Expansion Amid Government Funding Reduction
AstraZeneca, vaccine manufacturing, UK investment, government funding, Labour administration, economic growth, pharmaceutical industry
2025 J.P. Morgan Healthcare Conference: Optimism, Innovation, and Shifting Landscapes
AI in healthcare, outpatient care expansion, pharmaceutical services, regulatory environment, deal activity, digital health, gene editing, Trump administration
Senate Grills RFK Jr. on Controversial Health Stances in Contentious HHS Secretary Confirmation Hearings
Robert F. Kennedy Jr., HHS Secretary nomination, Senate confirmation hearings, vaccine skepticism, chronic disease focus, public health policy, Trump administration
Julie Kim to Succeed Christophe Weber as Takeda’s CEO in 2026
Takeda, Julie Kim, Christophe Weber, CEO succession, pharmaceutical industry, leadership transition, biopharmaceutical company
Zentalis Pharmaceuticals Cuts Workforce by 40% to Advance WEE1 Inhibitor to Registrational Trial
Zentalis Pharmaceuticals, layoffs, WEE1 inhibitor, azenosertib, clinical trials, cancer treatment, biotech industry
Senate Hearing for RFK Jr. Amid Strong Public Support for Vaccine Access
RFK Jr., Senate hearing, vaccine access, public support, FDA-approved vaccines, Department of Health and Human Services nomination
FDA Names Dr. Sara Brenner as Acting Commissioner
FDA, Acting Commissioner, Dr. Sara Brenner, Medical Devices, Food Safety
Sarepta Therapeutics Reports Encouraging Two-Year Data for ELEVIDYS in Duchenne Muscular Dystrophy, Projecting $1 Billion in Sales
Sarepta Therapeutics, ELEVIDYS, Duchenne Muscular Dystrophy (DMD), Gene Therapy, Clinical Trial Results, Sales Projections
Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification
Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration
Tris Pharma’s Cebranopadol Shows Promising Results in Phase 3 Trial for Moderate-to-Severe Acute Pain Treatment
Cebranopadol, Tris Pharma, ALLEVIATE-1, Phase 3 Clinical Trial, Acute Pain Treatment, Dual-NMR Agonist, Opioid Crisis, Pain Management